Eli Lilly expects new drugs to drive 18% growth in 2024
Eli Lilly’s newest GLP-1 drugs, Mounjaro for diabetes and Zepbound for obesity, had a strong finish to 2023, with sales of USD 2.2bn and USD 0.18 bn respectively in the fourth quarter of the year.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.